Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 36.62M P/E - EPS this Y -34.60% Ern Qtrly Grth -
Income -44.22M Forward P/E -0.70 EPS next Y 33.10% 50D Avg Chg -34.00%
Sales 12M PEG - EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 3.36 EPS next 5Y - 52W High Chg -55.00%
Recommedations 2.00 Quick Ratio 1.63 Shares Outstanding 22.63M 52W Low Chg 31.00%
Insider Own 0.05% ROA -63.71% Shares Float 488.15M Beta 1.47
Inst Own 15.48% ROE - Shares Shorted/Prior 250.19K/290.51K Price 2.24
Gross Margin 100.00% Profit Margin - Avg. Volume 153,030 Target Price 9.50
Oper. Margin -364.46% Earnings Date May 3 Volume 56,753 Change -5.49%
About ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

ASLAN Pharmaceuticals Limited News
05/02/24 ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
04/30/24 ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
04/24/24 ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
04/22/24 ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
04/19/24 ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
04/12/24 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
04/09/24 Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
03/27/24 Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
03/20/24 Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
03/12/24 ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
03/12/24 ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
03/11/24 ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
03/06/24 ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
02/29/24 ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
01/08/24 ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
01/02/24 ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
12/12/23 ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
11/20/23 ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
06:00 AM ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
10/27/23 ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ASLN Chatroom

User Image Kaz007 Posted - 1 day ago

$ASLN Why it does not move even good news came out? WHY?

User Image Stock_Titan Posted - 1 day ago

$ASLN ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics https://www.stocktitan.net/news/ASLN/aslan-pharmaceuticals-announces-expansion-of-its-collaboration-with-08s7tfemcvci.html

User Image Kaz007 Posted - 1 day ago

$ASLN Short should be destroyed.

User Image Stormra Posted - 2 days ago

$ASLN

User Image McDeal Posted - 04/30/24

$ASLN

User Image Kaz007 Posted - 04/30/24

$ASLN good move. It might be ready to go in May.

User Image RollingDollar Posted - 04/30/24

$ASLN

User Image EHeeze Posted - 04/30/24

$ASLN https://lifescievents.com/event/aslanpharma/

User Image lecorb Posted - 04/30/24

$ASLN https://finance.yahoo.com/news/aslan-pharmaceuticals-host-kol-panel-110000665.html

User Image Stock_Titan Posted - 04/30/24

$ASLN ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab https://www.stocktitan.net/news/ASLN/aslan-pharmaceuticals-to-host-kol-panel-discussion-on-treatment-rlrvkjw3xq8y.html

User Image RollingDollar Posted - 04/29/24

$ASLN

User Image RollingDollar Posted - 04/29/24

$ASLN .

User Image johnkimble Posted - 04/29/24

$ASLN we have been building a position and stepping up the pace no issue crossing the bid/ask spread to get volume on today and will keep paying up until at least 50 cents. This stock should be $5 but AI/algo funds are shorting it since the cash runway only shows months; they fail to see this company can easily get more cash when needed and dilution vs value is quite small Tagging my friends in $NKTR here

User Image casey88307 Posted - 04/29/24

$ASLN 📈

User Image RallyRaider Posted - 04/29/24

$ASLN is gonna flash 1$ anytime soon.

User Image mimiwor Posted - 04/28/24

$ASLN It seems they have couple near term catalyst.

User Image mimiwor Posted - 04/27/24

$ASLN

User Image Happy_Feet19 Posted - 04/26/24

$ASLN I calculate they have CASH until July, 2024. Can anybody confirm that guess?

User Image casey88307 Posted - 04/26/24

$ASLN 📈

User Image mimiwor Posted - 04/26/24

$ASLN

User Image Kaz007 Posted - 04/26/24

$ASLN go $0.4? damn it..

User Image mimiwor Posted - 04/26/24

$ASLN I just love to buy company with potential when nobody wants it.

User Image mimiwor Posted - 04/26/24

$ASLN buying 10k shares every cents.

User Image Bottleinthesmoke Posted - 04/26/24

$ASLN Soooooo manipulated but time is on our side.

User Image McDeal Posted - 04/26/24

$ASLN Relatively low flow positive news $9 price target I think I'll add some here.

User Image Kaz007 Posted - 04/26/24

$ASLN What a Singapore Scam.

User Image Readus_ Posted - 04/25/24

$ASLN Via a June 22, 2023 PR, ASLN announced its entry into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan. https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-enters-strategic-licensing-deal-zenyaku

User Image mimiwor Posted - 04/25/24

$ASLN

User Image RollingDollar Posted - 04/25/24

$ASLN

User Image McDeal Posted - 04/25/24

@TraderBucknKY @Readus_its manipulation on theese low floating penny stocks and all about liquidity when positive news is released retailers run it up and then the big money wants our shares and cheap so they barrow the float ( just over 20m on $ASLN )sell it (short) triggering stop losses and boom there's the liquidity. If the news is significant its sometimes better to let it settle back down and simmer a bit then look for long play opportunities. .Just saying, and hope this helps.

Analyst Ratings
HC Wainwright & Co. Buy Apr 23, 24
HC Wainwright & Co. Buy Apr 15, 24
HC Wainwright & Co. Buy Mar 18, 24
Piper Sandler Overweight Mar 13, 24
Piper Sandler Overweight Mar 11, 24
HC Wainwright & Co. Buy Nov 6, 23
Roth MKM Buy Aug 14, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy Jul 7, 23